Phathom Pharmaceuticals, Inc.

NASDAQ (USD): Phathom Pharmaceuticals, Inc. (PHAT)

Last Price

8.74

Today's Change

-0.23 (2.56%)

Day's Change

8.61 - 9.01

Trading Volume

170,955

Overview

Market Cap

593 Million

Shares Outstanding

68 Million

Avg Volume

1,341,111

Avg Price (50 Days)

15.06

Avg Price (200 Days)

12.24

PE Ratio

-1.51

EPS

-5.74

Earnings Announcement

04-Mar-2025

Previous Close

8.97

Open

8.90

Day's Range

8.61 - 9.0129

Year Range

6.065 - 19.71

Trading Volume

178,533

Price Change Highlight

1 Day Change

-3.23%

5 Day Change

-3.77%

1 Month Change

-49.77%

3 Month Change

-46.75%

6 Month Change

-13.89%

Ytd Change

-5.34%

1 Year Change

22.25%

3 Year Change

-53.68%

5 Year Change

-66.09%

10 Year Change

-64.72%

Max Change

-64.72%

News and Blogs
Latest Hottest Following

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment